SCHEMBL17872138

SCHEMBL17872138

COC(=O)CCCNC(=O)C(CCCNC(=O)OCc1ccccc1)NC(=O)OC(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.56
KLK7 P49862 2/20 0.56
KLK5 Q9Y337 2/20 0.56
ITGB3 P05106 1/20 0.53
ITGA2B P08514 1/20 0.53
CTSS P25774 2/20 0.52
CTSK P43235 1/20 0.52
CAPN1 P07384 1/20 0.52
CAPN2 P17655 1/20 0.52
CPB1 P15086 1/20 0.51
CPB2 Q96IY4 1/20 0.51
HTT P42858 1/20 0.51
CTSL P07711 1/20 0.51
PTGER4 P35408 1/20 0.51
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.50
FOLH1 Q04609 1/20 0.50
SIRT2 Q8IXJ6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17872140 0.96 KLK7 (0.53) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL5651760 0.96 MAPT (0.57) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL17872143 0.91 KLK7 (0.52) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL29454880 0.90 MAPT (0.60) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL30859242 0.90 MAPT (0.62) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL12085041 0.89 MAPT (0.62) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL12667695 0.89 MAPT (0.59) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL5996732 0.89 CTSK (0.61) MAPTKLK7KLK5ITGB3ITGA2B
SCHEMBL4857149 0.89 MAPT (0.58) MAPTKLK7KLK5CTSSCTSK
SCHEMBL30638285 0.89 MEN1 (0.60) MAPTKLK7KLK5CAPN1CAPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10434186-B2 Functionalized linear ligands and complexes thereof LUMIPHORE, INC. (US) 2019-10-08 US disclosed
US-10434186-B2 Functionalized linear ligands and complexes thereof LUMIPHORE, INC. (US) 2019-10-08 US disclosed
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. 2017-12-21 US disclosed
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. 2017-12-21 US disclosed
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. 2017-12-21 US disclosed
EP-3237429-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF Lumiphore, Inc. (US) 2017-11-01 EP disclosed
WO-2016106241-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. (US) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF CLTB, CLTA, EPCAM MAPT 1163/4885KLK7 1145/4885KLK5 1322/4885
US-10434186-B2 Functionalized linear ligands and complexes thereof CLTB, CLTA, EPCAM MAPT 1163/4885KLK7 1145/4885KLK5 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.